期刊文献+

N-乙酰半胱氨酸对冠状动脉介入治疗后对比剂肾病的预防作用 被引量:5

The Preventive Effects of N-Acetylcysteine on Contrast-Induced Nephropathy in Patients Undergoing Elective Percutaneous Coronary Intervention
下载PDF
导出
摘要 目的探讨N-乙酰半胱氨酸(NAC)对择期经皮冠状动脉介入治疗(PCI)术后发生对比剂肾病(CIN)是否具有预防作用。方法选取行择期PCI术的患者521例,随机分为NAC组和常规治疗组,其中NAC组260例,给予NAC+水化治疗;常规治疗组261例,仅给予水化治疗。观察2组PCI术前及术后72h血肌酐(Scr)、尿素氮(BUN)、肌酐清除率(Ccr)、C-反应蛋白(CRP)、β2微球蛋白(β2-MG)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、过氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GPX)及CIN发病率的变化。结果 (1)NAC组的CIN发病率(6.2%)与常规治疗组(3.8%)差异无统计学意义(χ2=1.48,P>0.05)。(2)2组PCI术前的血Scr、BUN、Ccr、CRP、β2-MG、TNF-α、IL-6、SOD及GPX水平差异无统计学意义(P>0.05)。(3)PCI术后72h,2组CRP、SOD、GPX均较术前升高(P<0.05);NAC组CRP、SOD、GPX水平低于常规治疗组(P<0.05);NAC组Scr、BUN、β2-MG、Ccr水平较常规治疗组无明显变化(P>0.05)。结论 NAC对PCI术后CIN的发生可能无预防作用。 Objective To investigate the preventive effect of N-acetylcysteine (NAC) on contrast-induced nephropa- thy (CIN) in patients undergoing elective percutaneous coronary intervention (PCI). Methods A total of 521 patients underwent PCI in Tianjin were randomly divided into conventional treatment group (n--261) and NAC treatment group (n=260). NAC treatment group was given oral NAC (600 mg twice daily) for 48 h and 72 h before PCI plug hydration therapy, and the conventional treatment group was given only hydration therapy. The serum levels of creatinine (Scr), urea nitrogen (BUN), creatinine clearance rate (Cer), C-reactive protein (CRP), ~2-microglobulin(~2-MG), tumor necrosis factor-a (TNF-a), inter- leukin-6 (IL-6), superoxide dismutase (SOD), glutathione peroxidase (GPX) and incidence of CIN were detected at admission and 72 h after the procedure. Results (1) There was no significant difference in the incidence of CIN between NAC treatment group (6.2%) and conventional treatment group (3.8%, X2=1.48, P 〉 0.05). (2) There were no significant differences in serum levels of Scr, BUN, Cer, CRP,x2-MG, TNF-oL, IL-6, SOD and GPX before PCI ( P 〉 0.05). (3) The serum levels of CRP, SOD and GPX were significantly higher 72 h after the procedure in two groups ( P 〈 0.05). There were significantly lower se- rum levels in CRP, SOD and GPX in NAC treatment group than those of conventional treatment group ( P 〈0.05). There were no significant differences in serum levels of Scr, BUN, x2-MG and Ccr between NAC treatment group and conventional treat- ment group ( P 〉 0.05). Conclusion N-acetylcysteine may have no beneficial effect on the prevention of CIN after PCI.
出处 《天津医药》 CAS 北大核心 2013年第7期636-639,共4页 Tianjin Medical Journal
基金 天津市卫生局级重点攻关项目(项目编号:10KG122)
关键词 乙酰半胱氨酸 肾疾病 造影剂 碘帕醇 血管成形术 经腔 经皮冠状动脉 对比剂肾病 acetylcysteine kidney diseases contrast media iopamidol angioplasty, transluminal, percutaneous coro-nary contrast induced nephropathy
  • 相关文献

参考文献11

  • 1Toprak O. Risk markers for contrast induced nephropathy[J].Am J Med Sci, 2007,334(4):283-290.
  • 2杨世诚,陈永利,刘园园,张莹莹,刘晓罡,付乃宽.经皮冠状动脉介入治疗术后对比剂肾病发病率及危险因素分析[J].天津医药,2011,39(10):903-906. 被引量:18
  • 3Cho JY, Jeong MH, Hwan Park S,et al. Effect of contrast-induced nephropathy oncardiac outcomes after use of nonionic isosmolar contrast media during coronaryrocedure[J]. J Cardiol,2010,56(3): 300-306.
  • 4Heyman SN, Rosen S, Khamaisi M,et al. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy[J].Invest Radiol,2010,45 (4): 188-195.
  • 5汪斌,刘志忠,张丰富.冠状动脉介入诊治中高敏C反应蛋白与造影剂肾病的相关性分析[J].中国医药,2007,2(8):457-459. 被引量:35
  • 6Saleh MA, Mahran OM, Bassam Al-Salahy M. Circulating oxidative stress status in dromedary camels infested with sarcoptic mange[J]. Vet Res Commun,2011, 35 (1): 35-45.
  • 7Marenzi G, Assanelli E, Marana I, Bartorelli AL. N-acetylcys teine and contrast induced nephropathy in primary angioplasty[J]. N Engl J Med,2006,354 (26): 2773-2782.
  • 8Tepel M, van der Giet M, Schwarzfeld C,et al. Prevention of radio- graphic contrast agent induced reductions in renal function by acet- ylcysteine[J]. N Engl J Med,2000,343(3): 180-184.
  • 9Gomes VO, Caramori P, Lasevitch R, et al. N-acetylcysteine does not prevent contrast Induced nephropathy after cardiac catheterisa- tion with an ionic low osmolality contrast medium: a multicentre clinical trial[J]. Heart,2005,91 (6):774-778.
  • 10ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiogra- phy: main results from the randomized Acetylcysteine for Contrast induced nephropathy Trial (ACT) [J].Circulation,2011,124(11): 1250-1259.

二级参考文献15

  • 1Toprak O. Risk markers for contrast induced nephropathy[J].Am J Med Sci, 2007,334(4):283-290.
  • 2Cho JY, Jeong MH, Hwan Park S,et al. Effect of contrast-induced nephropathy on cardiac outcomes after use of nonionic isosmolar contrast media during coronary procedure[J]. J Cardiol,2010,56(3): 300-306.
  • 3Rosenstock JL, Gilles E, Geller AB,et al. Impact of heart failure on the incidence of contrast-induced nephropathy in patients with- chronic kidney disease[J]. Int Urol Nephrol,2010,42(4):1049-1054.
  • 4Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction[J]. J Am Coll Cardiol, 2004,44(9):1780-1785.
  • 5Senoo T, Motohiro M, Kamihata H,et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome[J].Am J Cardiol, 2010, 105(5): 624-628.
  • 6Hernandez F, Mora L, Garcia-Tejada J,et al. Comparison of iodixanol and ioversol for the prevention of contrast-induced nephropathy in diabetic patients after coronary angiography or angioplasty[J].Rev Esp Cardiol, 2009, 62(12): 1373-1380.
  • 7Reed MC, Moscucci M, Smith DE,et al.The relative renal safety of iodixanol and low-osmolar contrast media in patients undergoing percutaneous coronary intervention. Insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) [J].J Invasive Cardiol,2010,22( 10):467-472.
  • 8Sakkinen P;Abbott RD;Curb JD.C-reactive protein and myocardial infarction[J],2002(05).
  • 9Bradford M E.levation of C-reactioon in "active" coronary artery disease,1990(02).
  • 10Duan SB;Wu HW;Luo JA.Assessment of renal function in early stages of nephrotoxicity Inducd by iodinated contrastmedia[J],1999(02).

共引文献50

同被引文献115

  • 1扆恒亮,谭宁,邓宇珺.N-乙酰半胱氨酸和碳酸氢钠预防中重度肾功能不全患者对比剂肾损害的作用[J].岭南心血管病杂志,2009,15(5):347-349. 被引量:4
  • 2丁晓隽,李慧华.急性冠状动脉综合征患者介入治疗中N-乙酰半胱氨酸对造影剂相关性肾病保护作用的临床研究[J].中华临床医师杂志(电子版),2011,5(15):4499-4501. 被引量:3
  • 3STACUL F, MOLEM AJ, REIMER P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines[J]. Eur Radol, 2011, 21(12): 2527-2541.
  • 4FERRARIO F, BARONE MT, LANDONI G, et al. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy-a randomized controlled study[J]. Nepbrol Dial Transplant, 2009, 24(10): 3103-3107.
  • 5GOMES VO, FIGUREDO CEPD, CARAMORI P, et aL N-aeetylcysteine does not prevent contrast induced nephmpathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical triM[J]. Heart, 2005, 91(6): 774- 778.
  • 6OZCAN EE, GUNERI S, AKDENIZ B, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures A single-center prospective controlled trial[J~ American Heart Journal, 2007, 154(3): 539-544.
  • 7BASKURT M, OKCUN B, ABACI O, et al. N-acetylcysteine versus N-acetylcysteine+theophylline for the prevention of contrast nephropathy[J]. European Journal of Clinical Investigation, 2009, 39(9): 793-799.
  • 8THIELE H, HILDEBRAND L, SCHIRDEWAHN C, et al. Impact of high-dose N-acetyIcysteine versus placebo on contrast induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J} Journal of the American College of Cardiology, 2010, 55(20): 2201-2209.
  • 9AMINI M, SALARIFAR M, AMIRBAIGLOO A, et al. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial[J]. Trials, 2009, 10: 45.
  • 10RASHID ST, SALMAN M, MYINT F, et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acety [eysteine[J], Journal of Vascular Surgery, 2004, 40(6): 1136-1141.

引证文献5

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部